Table 4 Major pharmaceutical compounds in clinical development for the treatment of thyroid cancer
From: Genetic mutations in the treatment of anaplastic thyroid cancer: a systematic review
Pharmaceutical compound | VEGFRs | RET/PTC | BRAF | PDFGR | mTORC1 |
|---|---|---|---|---|---|
Axitinib | + | Â | - | + | - |
Cabozantinib | +/- | Â | - | - | - |
Lenvatinib | + | Â | - | + | - |
Motesanib | + | Â | - | + | - |
Pazopanib | + | Â | - | + | - |
Sorafenib | + | + | + | + | - |
Sunitinib | + | + | - | + | - |
Vandetanib | + | + | - | - | - |
Vemurafenib | - | - | + | - | - |
Everolimus | - | - | - | - | + |